Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
27 05 2020
27 05 2020
Historique:
received:
15
03
2020
accepted:
12
05
2020
revised:
02
05
2020
entrez:
29
5
2020
pubmed:
29
5
2020
medline:
5
5
2021
Statut:
epublish
Résumé
In total, 279 patients with hairy-cell leukemia (HCL) were analyzed, with a median follow-up of 10 years. Data were collected up to June 2018. We analyzed responses to treatment, relapses, survival, and the occurrence of second malignancies during follow-up. The median age was 59 years. In total, 208 patients (75%) were treated with purine analogs (PNAs), either cladribine (159) or pentosatin (49), as the first-line therapy. After a median follow-up of 127 months, the median overall survival was 27 years, and the median relapse-free survival (RFS) was 11 years. The cumulative 10-year relapse incidence was 39%. In patients receiving second-line therapy, the median RFS was 7 years. For the second-line therapy, using the same or another PNA was equivalent. We identified 68 second malignancies in 59 patients: 49 solid cancers and 19 hematological malignancies. The 10-year cumulative incidences of cancers, solid tumors, and hematological malignancies were 15%, 11%, and 5.0%, respectively, and the standardized incidence ratios were 2.22, 1.81, and 6.67, respectively. In multivariate analysis, PNA was not a risk factor for second malignancies. HCL patients have a good long-term prognosis. PNAs are the first-line treatment. HCL patients require long-term follow-up because of their relatively increased risk of second malignancies.
Identifiants
pubmed: 32461544
doi: 10.1038/s41408-020-0328-z
pii: 10.1038/s41408-020-0328-z
pmc: PMC7253459
doi:
Substances chimiques
Antineoplastic Agents
0
Pentostatin
395575MZO7
Cladribine
47M74X9YT5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
62Références
Blood. 1994 May 15;83(10):2931-8
pubmed: 8180388
Br J Haematol. 2016 Nov;175(3):402-409
pubmed: 27351754
J Clin Oncol. 1995 Apr;13(4):974-82
pubmed: 7707126
Hematol Oncol. 2015 Dec;33(4):192-8
pubmed: 25393847
Am J Hematol. 2017 Dec;92(12):1382-1390
pubmed: 29110361
Br J Haematol. 1995 Sep;91(1):154-61
pubmed: 7577624
Best Pract Res Clin Haematol. 2015 Dec;28(4):217-29
pubmed: 26614900
Br J Haematol. 2009 Jun;145(6):733-40
pubmed: 19344416
Haematologica. 2001 Oct;86(10):1046-50
pubmed: 11602410
Leukemia. 1987 Apr;1(4):405
pubmed: 3669765
Eur J Haematol. 2009 Sep;83(3):246-50
pubmed: 19302557
Br J Haematol. 2009 Jan;144(1):2
pubmed: 18950465
J Natl Cancer Inst. 2007 Feb 7;99(3):215-22
pubmed: 17284716
Leuk Lymphoma. 2014 May;55(5):1007-12
pubmed: 23885799
Br J Haematol. 2015 Oct;171(1):84-90
pubmed: 26115047
Leukemia. 2018 Aug;32(8):1768-1777
pubmed: 30030507
Leukemia. 2003 Jan;17(1):45-51
pubmed: 12529659
J Hematol Oncol. 2010 Oct 04;3:35
pubmed: 20920342
J Natl Cancer Inst Monogr. 2014 Aug;2014(48):115-24
pubmed: 25174032
Rom J Morphol Embryol. 2013;54(3):575-9
pubmed: 24068406
Blood. 1958 Jul;13(7):609-30
pubmed: 13560561
N Engl J Med. 2011 Jun 16;364(24):2305-15
pubmed: 21663470
Rev Epidemiol Sante Publique. 2014 Apr;62(2):95-108
pubmed: 24613140
Curr Med Res Opin. 2015 Jan;31(1):17-23
pubmed: 25265129
Blood. 1998 Aug 15;92(4):1160-4
pubmed: 9694703
Leukemia. 2004 Sep;18(9):1476-81
pubmed: 15229616
Br J Haematol. 2016 Sep;174(5):760-6
pubmed: 27301277
N Engl J Med. 1990 Apr 19;322(16):1117-21
pubmed: 1969613
Cancer. 1992 Oct 15;70(8):2087-90
pubmed: 1394039
Blood. 2000 Nov 1;96(9):2981-6
pubmed: 11049974
Leuk Lymphoma. 1996 Jun;22(1-2):103-6
pubmed: 8724535
Best Pract Res Clin Haematol. 2015 Dec;28(4):193-9
pubmed: 26614897
Turk J Haematol. 2017 Dec 1;34(4):291-299
pubmed: 29199176
N Engl J Med. 2015 Oct 29;373(18):1733-47
pubmed: 26352686
Leuk Lymphoma. 1999 Nov;35(5-6):555-65
pubmed: 10609793
Scand J Work Environ Health. 1996 Aug;22(4):285-93
pubmed: 8881017
Rev Epidemiol Sante Publique. 2016 Apr;64(2):103-12
pubmed: 26973179
Best Pract Res Clin Haematol. 2015 Dec;28(4):175-9
pubmed: 26614895
Blood. 2014 Jan 9;123(2):177-83
pubmed: 24192579
Blood. 1998 Sep 15;92(6):1918-26
pubmed: 9731048
Semin Oncol. 2000 Apr;27(2 Suppl 5):32-6
pubmed: 10877049
Cancer Res. 1979 Jul;39(7 Pt 1):2366-70
pubmed: 445435
J Clin Oncol. 2003 Mar 1;21(5):891-6
pubmed: 12610190
Cancer. 2010 Oct 15;116(20):4788-92
pubmed: 20597132
Eur J Haematol. 2006 Nov;77(5):372-7
pubmed: 17044834
Br J Haematol. 2014 Aug;166(3):390-400
pubmed: 24749839
J Clin Oncol. 2002 Feb 1;20(3):638-46
pubmed: 11821443
Blood. 1994 Nov 1;84(9):3242-4
pubmed: 7949198
Blood. 1966 Feb;27(2):199-211
pubmed: 5322749
Indian J Hematol Blood Transfus. 2014 Mar;30(1):59-61
pubmed: 24554827
Am J Hematol. 1984 May;16(4):393-401
pubmed: 6720683
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):857-862
pubmed: 28778620
J Clin Oncol. 1997 May;15(5):1803-10
pubmed: 9164188
Leuk Lymphoma. 2002 May;43(5):1043-9
pubmed: 12148884
N Engl J Med. 1984 Jan 5;310(1):15-8
pubmed: 6689734